DVL3 and nonpapillary renal cell carcinoma: Therefore, the development of therapeutic agents targeted to inhibit DVL3, might allow for a longer overall and/or disease-specific survival in patients who are diagnosed with metastatic ccRCC with a high expression level of DVL3.